Aesthetic medical device startup Innosus said on Tuesday it raised 14.2 billion won in Series A funding from investors including Altos Ventures.

Innosus said part of the funding was structured as a secondary share sale by Tail Ventures, an investor that identified Innosus at the seed stage. The company said it will use the funding as a springboard to step up its push into the global aesthetic medical device market.

Innosus, founded in February 2022, is an innovative medical device company that developed Alltite, which applies cancer treatment technology to aesthetic lifting. Its chief executive Jae-yong Shim (심재용) is a physician-turned-founder who graduated as valedictorian from Seoul Science High School and graduated from Seoul National University College of Medicine, and has built multiple startup and clinical experiences in the diet and beauty industry.

The company said Alltite's core competitiveness is DLTD (Dermis Layer Target Dielectric heating system) technology, for which an international patent has been filed. It said the technology applies the principle of dielectric heating, previously used in cancer treatment and rehabilitation treatment, to an aesthetic medical device.

Some existing lifting devices can cause pain and energy loss as heat energy is delivered into the skin and the epidermal layer temperature rises. The company said the DLTD technology is an internal heating method that concentrates heat in the mid-to-lower dermis, minimizing energy loss and preventing a rise in epidermal temperature, reducing pain to a level that allows procedures without anesthesia.

Alltite secured export contracts for more than 300 units in Japan, Hong Kong and Brazil ahead of its domestic launch, and recorded sales of more than 200 units within 10 months of launch.

Jae-yong Shim said, "This investment round is the result of recognition of Innosus' technological capabilities and growth potential." He said the company plans to accelerate entry into global markets including North America, Europe and Asia, and expand R&D investment for next-generation product development.